New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
Source:
Nasdaq GlobeNewswire
/
06 Apr 2024 14:30:00 America/Chicago
N/A
Share on,